<DOC>
	<DOCNO>NCT02266472</DOCNO>
	<brief_summary>The purpose trial investigate bioequivalence newly develop fix dose combination ( FDC ) tablet contain empagliflozin metformin extend release compare free combination empagliflozin metformin extend release fed condition .</brief_summary>
	<brief_title>Bioequivalence Fixed Dose Combination Tablet Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets Healthy Male Female</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Healthy male female subject age 18 55 year body mass index ( BMI ) 18.5 29.9 kg/m2 additional inclusion criterion may apply Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg diastolic blood pressure outside range 50 90 mmHg pulse rate outside range 45 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract could interfere kinetics trial medication Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological disorder psychiatric disorder additional exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>